Patients with metastatic melanoma and a mutation in the BRAF gene can be both treated with immunotherapy, including anti-CTLA4+anti-PD1 combination therapy or targeted therapy with BRAF and MEK inhibitors. This evidence concerns the gene BRAF and metastatic melanoma.